Media
A focused approach to a hard cancer problem.
Evolvia BioPharma develops isoform-selective PHD1 inhibitors to restore chemosensitivity in MSS colorectal cancer.
Core message
The gap
MSS colorectal cancer doesn't respond to immunotherapy and eventually resists chemotherapy. No approved agent restores that sensitivity.
The approach
Selective PHD1 inhibition primes a latent p53 death program; standard chemotherapy activates it.
The differentiation
Isoform selectivity avoids the HIF-driven toxicity that limited the entire pan-PHD class.
Media inquiries: contact us.